

Ex. number: 194-00-19/05.06.2023

Conditional capital increase in connection with a resolution of the General Meeting of the holders of warrants with ISIN BG9200001212 held on 2 June 2023

Sofia, Bulgaria, June 5, 2023 - Pursuant to the requirements of Article 100t of the Securities Act, **Sopharma AD** (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) announces that at its meeting the Board of Directors of the Company resolved to increase the capital on the condition that the shares from the increase are subscribed by the warrant holders, based on a resolution legally adopted at the General Meeting of Warrantholders (GMW) on June 2, 2023. This notification is not a notification pursuant to art. 89t of the Law on Public Offering of Securities.

The expected timetable for implementing the increase is as follows:

Date of disclosure of the announcement under Article 89t(2) of the Securities Act on the website www.x3news.com , on the websites of Sopharma AD and the authorised investment intermediary Sofia International Securities AD	24 August 2023
Commencement date for the exercise of the warrants	1 September 2023
Closing date for payment and subscription of shares	26 September 2023
Registration of the issue of new shares and capital increase in the Commercial Register *	2 October 2023
Registration of the new shares in investors' accounts with the Central Depository *	10 October 2023
Registering the capital increase in the FSC register under art. 30 from the Law on the Financial Supervision Commission *	17 or 19 October 2023
Commencement of trading in the new shares on the BSE *	30 October 2023

* in accordance with the deadlines of the relevant institution

Please, on the basis of Art. 100k, para. 1 of the LPA to give publicity to the above information.

Attachments: Minutes of the meeting of the Board of Directors



Pelagia Viatcheva

Director of Investor Relations

Information about the company

Sopharma AD

90 years of tradition and modernity - modern production, European standards and quality of production, corporate social responsibility.

Sopharma is the most successful Bulgarian company after privatization and since 2000 the company has realized 10 times growth in market capitalization and 25 times growth in revenues. Over the last 10 years, Sopharma has been the first largest pharmaceutical company in Bulgaria in terms of revenue.

Sopharma produces active substances and pharmaceutical products; carries out research, development and implementation activities in the field of phytochemistry, chemistry and pharmaceuticals, provides manufacturing and other related services.

With 9 pharmaceutical factories in the country and the only ampoule plant of its kind in the country, the company produces 3 billion tablets, 20 million pieces of syrup forms, has marketing authorization for more than 200 generic products, 15 traditional products, 12 of which are plant-based, and incorporates more than 1,500 tons of medicinal plants in its products.

Sopharma plays an active and key role in raising the standard of living, in making people healthier, happier and more protected. Sopharma continuously invests in new technologies, innovation, research and exploration. The company maintains a constant and effective dialogue with all the players in the pharmaceutical industry who contribute to improving the healthcare system.

Sopharma Group

The Sopharma Group is a vertically integrated healthcare business that operates in important sectors such as the manufacture of pharmaceuticals and consumables for the hospital market, distribution of pharmaceuticals and many others.